The Europe Antibody Drug Conjugates Market would witness market growth of 13.8% CAGR during the forecast period (2022-2028).
Antigens expressed predominantly on the surface of tumor cells are ideal targets for ADCs. Hematological malignancies express lineage-specific antigens, which have been intensively investigated as excellent candidates, with many particular ADCs already approved and others in research. However, lineage-specificity does not apply to solid tumors, because antigens are mostly "tumor-associated" rather than "tumor-specific," meaning they are expressed on tumor cells as well as normal cells. It means that all of these drugs have a portion of on-target/off-tumor toxicity that is reliant on normal cell expression of the specific target, as well as a lower quantity of intra-tumoral drug delivery.
Cancer is one of the most prevalent causes of mortality worldwide, accounting for 8.2 million deaths per year. Chemotherapy, radiation, immunotherapy, laser treatment, stem cell therapy, surgery, hyperthermia, photodynamic therapy, and other therapeutic approaches are used to treat cancer and tumors. In addition, chemotherapy was the primary therapeutic intervention for cancer treatment among these choices. This is based on the assumption that these drugs would not affect normal cells while killing quickly dividing tumor cells first. Nitrogen mustard was studied in people based on this premise, leading to the elimination of bone marrow and lymphoid tissues in cancer patients. DNA alkylation is how this chemotherapeutic drug causes cellular apoptosis.
The Europe region is witnessing the increasing incidence of cancer patients. As per 2015 data, the Department of Health and Social Care in the United Kingdom invests a substantial amount of money each year in cancer treatment and services. Biomarkers can be used to assess patients in a variety of clinical settings, such as estimating disease risk, screening for occult primary cancers, distinguishing benign from malignant findings or one type of malignancy from another, determining prognosis and prediction for cancer patients, and monitoring disease status, either to identify repeat or ascertain response or progression to therapy.
The unregulated development of abnormal cells in one or both lungs causes lung cancer. Regardless of the fact that lung cancer can infect persons who have never smoked, smokers are at the highest risk. Lung cancer risk rises with the length of time and amount of cigarettes smoked. At the work or in the environment, other risk factors comprise asbestos, some metals, secondhand smoke, some organic chemicals, and air pollution, radiation, and diesel emissions.
The Germany market dominated the Europe Antibody Drug Conjugates Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $920.6 Million by 2028. The UK market is anticipated to grow at a CAGR of 12.8% during (2022 - 2028). Additionally, The France market would showcase a CAGR of 14.6% during (2022 - 2028).
Based on Application, the market is segmented into Breast Cancer, Blood Cancer, Urothelial Cancer & Bladder Cancer, and Others. Based on Technology, the market is segmented into Cleavable Linker, Non-Cleavable Linker, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Antibody Drug Conjugates Market Size will Hit $13.8 Billion by 2028, at a CAGR of 14.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, GlaxoSmithKline PLC, Pfizer, Inc., Astellas Pharma, Inc., Gilead Sciences, Inc., Seagen, Inc., ADC Therapeutics SA, and Daiichi Sankyo Company, Limited.
Scope of the Study
Market Segments Covered in the Report:
By Application
- Breast Cancer
- Blood Cancer
- Urothelial Cancer & Bladder Cancer
- Others
By Technology
- Cleavable Linker
- Non-Cleavable Linker
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Takeda Pharmaceutical Company Limited
- F. Hoffmann-La Roche Ltd.
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Pfizer, Inc.
- Astellas Pharma, Inc.
- Gilead Sciences, Inc.
- Seagen, Inc.
- ADC Therapeutics SA
- Daiichi Sankyo Company, Limited
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Antibody Drug Conjugates Market, by Application
1.4.2 Europe Antibody Drug Conjugates Market, by Technology
1.4.3 Europe Antibody Drug Conjugates Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition & mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, May – 2022, Mar) Leading Players
Chapter 4. Europe Antibody Drug Conjugates Market by Application
4.1 Europe Breast Cancer Market by Country
4.2 Europe Blood Cancer Market by Country
4.3 Europe Urothelial Cancer & Bladder Cancer Market by Country
4.4 Europe Others Market by Country
Chapter 5. Europe Antibody Drug Conjugates Market by Technology
5.1 Europe Cleavable Linker Market by Country
5.2 Europe Non-Cleavable Linker Market by Country
5.3 Europe Others Market by Country
Chapter 6. Europe Antibody Drug Conjugates Market by Country
6.1 Germany Antibody Drug Conjugates Market
6.1.1 Germany Antibody Drug Conjugates Market by Application
6.1.2 Germany Antibody Drug Conjugates Market by Technology
6.2 UK Antibody Drug Conjugates Market
6.2.1 UK Antibody Drug Conjugates Market by Application
6.2.2 UK Antibody Drug Conjugates Market by Technology
6.3 France Antibody Drug Conjugates Market
6.3.1 France Antibody Drug Conjugates Market by Application
6.3.2 France Antibody Drug Conjugates Market by Technology
6.4 Russia Antibody Drug Conjugates Market
6.4.1 Russia Antibody Drug Conjugates Market by Application
6.4.2 Russia Antibody Drug Conjugates Market by Technology
6.5 Spain Antibody Drug Conjugates Market
6.5.1 Spain Antibody Drug Conjugates Market by Application
6.5.2 Spain Antibody Drug Conjugates Market by Technology
6.6 Italy Antibody Drug Conjugates Market
6.6.1 Italy Antibody Drug Conjugates Market by Application
6.6.2 Italy Antibody Drug Conjugates Market by Technology
6.7 Rest of Europe Antibody Drug Conjugates Market
6.7.1 Rest of Europe Antibody Drug Conjugates Market by Application
6.7.2 Rest of Europe Antibody Drug Conjugates Market by Technology
Chapter 7. Company Profiles
7.1 Takeda Pharmaceutical Company Limited
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expense
7.1.1 Recent strategies and developments:
7.1.1.1 Partnerships, Collaborations, and Agreements:
7.1.1.2 Acquisitions and Mergers:
7.2 F. Hoffmann-La Roche Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.3 AstraZeneca PLC
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.4 GlaxoSmithKline PLC
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.5.2 Approvals and Trials:
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional & Segmental Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations and Agreements:
7.6 Astellas Pharma, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.6.5.2 Approvals and Trials:
7.7 Gilead Sciences, Inc.
7.7.1 Company overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expenses
7.7.4 Recent strategies and developments:
7.7.4.1 Acquisitions and Mergers:
7.7.4.2 Partnerships, Collaborations and Agreements:
7.8 Seagen, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Research & Development Expenses
7.8.4 Recent strategies and developments:
7.8.4.1 Partnerships, Collaborations, and Agreements:
7.9 ADC Therapeutics SA
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Research & Development Expenses
7.9.4 Recent strategies and developments:
7.9.4.1 Partnerships, Collaborations, and Agreements:
7.9.4.2 Approvals and Trials:
7.10. Daiichi Sankyo Company, Limited
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Research & Development Expense
7.10.4 Recent strategies and developments:
7.10.4.1 Partnerships, Collaborations, and Agreements:
TABLE 1 Europe Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 2 Europe Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Antibody Drug Conjugates Market
TABLE 4 Acquisition & mergers – Antibody Drug Conjugates Market
TABLE 5 Approvals and trials– Antibody Drug Conjugates Market
TABLE 6 Europe Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 7 Europe Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 8 Europe Breast Cancer Market by Country, 2018 - 2021, USD Million
TABLE 9 Europe Breast Cancer Market by Country, 2022 - 2028, USD Million
TABLE 10 Europe Blood Cancer Market by Country, 2018 - 2021, USD Million
TABLE 11 Europe Blood Cancer Market by Country, 2022 - 2028, USD Million
TABLE 12 Europe Urothelial Cancer & Bladder Cancer Market by Country, 2018 - 2021, USD Million
TABLE 13 Europe Urothelial Cancer & Bladder Cancer Market by Country, 2022 - 2028, USD Million
TABLE 14 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 15 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 16 Europe Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 17 Europe Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 18 Europe Cleavable Linker Market by Country, 2018 - 2021, USD Million
TABLE 19 Europe Cleavable Linker Market by Country, 2022 - 2028, USD Million
TABLE 20 Europe Non-Cleavable Linker Market by Country, 2018 - 2021, USD Million
TABLE 21 Europe Non-Cleavable Linker Market by Country, 2022 - 2028, USD Million
TABLE 22 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 23 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 24 Europe Antibody Drug Conjugates Market by Country, 2018 - 2021, USD Million
TABLE 25 Europe Antibody Drug Conjugates Market by Country, 2022 - 2028, USD Million
TABLE 26 Germany Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 27 Germany Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 28 Germany Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 29 Germany Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 30 Germany Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 31 Germany Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 32 UK Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 33 UK Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 34 UK Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 35 UK Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 36 UK Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 37 UK Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 38 France Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 39 France Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 40 France Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 41 France Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 42 France Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 43 France Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 44 Russia Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 45 Russia Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 46 Russia Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 47 Russia Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 48 Russia Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 49 Russia Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 50 Spain Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 51 Spain Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 52 Spain Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 53 Spain Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 54 Spain Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 55 Spain Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 56 Italy Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 57 Italy Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 58 Italy Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 59 Italy Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 60 Italy Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 61 Italy Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 62 Rest of Europe Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 63 Rest of Europe Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 64 Rest of Europe Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 65 Rest of Europe Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 66 Rest of Europe Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 67 Rest of Europe Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 68 Key Information – Takeda Pharmaceutical Company Limited
TABLE 69 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
TABLE 70 KEY INFORMATION – ASTRAZENECA PLC
TABLE 71 Key Information – GlaxoSmithKline PLC
TABLE 72 Key Information – Pfizer, Inc.
TABLE 73 key information – Astellas Pharma, Inc.
TABLE 74 Key Information – Gilead Sciences, Inc.
TABLE 75 Key Information – Seagen Inc.
TABLE 76 Key Information – ADC Therapeutics SA
TABLE 77 Key Information – Daiichi Sankyo Company, Limited
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
FIG 4 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, May – 2022, Mar) Leading Players
FIG 5 Recent strategies and developments: Takeda Pharmaceutical Company Limited
FIG 6 Recent strategies and developments: Gilead Sciences, Inc.